VLA Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.13 |
| 52 Week High | €5.90 |
| 52 Week Low | €2.07 |
| Beta | 1.02 |
| 11 Month Change | -19.77% |
| 3 Month Change | -38.22% |
| 1 Year Change | -62.18% |
| 33 Year Change | -89.49% |
| 5 Year Change | -13.95% |
| Change since IPO | -80.53% |
Recent News & Updates
Recent updates
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Nov 10
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive
Sep 19Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 17Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 10Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Apr 05Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)
Mar 27Is Valneva (EPA:VLA) Weighed On By Its Debt Load?
Mar 15News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts
Jan 06Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?
Dec 13Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?
Aug 10Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry
May 12Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt
Jan 30Shareholder Returns
| VLA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -4.7% | -5.6% | -0.06% |
| 1Y | -62.2% | -26.5% | -2.5% |
Return vs Industry: VLA underperformed the French Biotechs industry which returned -28.2% over the past year.
Return vs Market: VLA underperformed the French Market which returned -2.1% over the past year.
Price Volatility
| VLA volatility | |
|---|---|
| VLA Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: VLA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: VLA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| VLA fundamental statistics | |
|---|---|
| Market cap | €346.50m |
| Earnings (TTM) | -€7.42m |
| Revenue (TTM) | €158.54m |
2.2x
P/S Ratio-46.7x
P/E RatioIs VLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLA income statement (TTM) | |
|---|---|
| Revenue | €158.54m |
| Cost of Revenue | €163.61m |
| Gross Profit | -€5.08m |
| Other Expenses | €2.34m |
| Earnings | -€7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | -3.20% |
| Net Profit Margin | -4.68% |
| Debt/Equity Ratio | 79.4% |
How did VLA perform over the long term?
See historical performance and comparison